Current and future treatment of pulmonary hypertension

Drugs of Today

Volumn 48, Issue 2, 2012, Pages 133-147

  Pabani, S ^a   Mousa, Shaker A ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Department of Pharmacology ^*  (United States)

Author keywords

Endothelin receptor antagonists; HMG CoA reductase inhibitors; Nitric oxide; Phosphodiesterase inhibitors; Prostacyclin; Pulmonary hypertension

Indexed keywords

AMBRISENTAN; ATORVASTATIN; BERAPROST; BOSENTAN; CICLETANINE; CITRULLINE; DAGLUTRIL; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; IMATINIB; MACITENTAN; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRAVASTATIN; PROSTACYCLIN; PROSTANOID; RIOCIGUAT; SELEXIPAG; SILDENAFIL; SIMVASTATIN; SITAXSENTAN; SORAFENIB; TADALAFIL; UNINDEXED DRUG; UNIPROST; VARDENAFIL;

ADD ON THERAPY; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COUGHING; DISEASE CLASSIFICATION; DIZZINESS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EXERCISE TOLERANCE; FATIGUE; FLUSHING; HEADACHE; HEART RIGHT VENTRICLE HYPERTROPHY; HOT FLUSH; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG FUNCTION; MONOTHERAPY; MORTALITY; MYALGIA; NONHUMAN; NOSE CONGESTION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PROGNOSIS; PROSTAGLANDINS; PROTEIN KINASE INHIBITORS; RECEPTORS, ENDOTHELIN; SEROTONIN ANTAGONISTS;

EID: 84858232841     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.2.1703662     Document Type: Review

References (60)

1. DiPiro, J.T. Pharmacotherapy: A Pathophysiologic Approach. McGraw-Hill Medical: 2008.
2. McLaughlin, V.V., Archer, S.L., Badesch, D.B. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119(16): 2250-94.
3. Fishman, A.P., Elias, J.A. Fishman's Pulmonary Diseases and Disorders. McGraw-Hill Medical: New York 2008, 1359-408.
4. Portillo, K., Santos, S., Madrigal, I. et al. [Study of the BMPR2 gene in patients with pulmonary arterial hypertension]. Arch Bronconeumol 2010, 46(3): 129-34.
5. Simonneau, G., Galie, N., Rubin, L. et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43(12, Suppl. S): 5S-12S. (Pubitemid 38759712)
6. Simonneau, G., Robbins, I.M., Beghetti, M. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(1, Suppl.): S43-54.
7. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Ed. Little, Brown & Co: Boston 1994, 253-6.
8. Shovlin, C.L., Angus, G., Manning, R.A. et al. Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension. PLoS One 2010, 5(2): e9154.
9. Cirillo, P., Cali, G., Golino, P. et al. Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 2004, 109(23): 2911-6. (Pubitemid 38780307)
10. O'Connell, K.A., Wood, J.J., Wise, R.P., Lozier, J.N. Braun, M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295(3): 293-8. (Pubitemid 43112957)
11. Ferreira, A.J., Shenoy, V., Yamazato, Y. et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009, 179(11): 1048-54.
12. Yamazato, Y., Ferreira, A.J., Hong, K.H. et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 2009, 54(2): 365-71.
13. Han, S.X., He, G.M., Wang, T. et al. Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme-2. Toxicol Appl Pharmacol 2010, 245(1): 100-7.
14. Archer, S.L., Marsboom, G., Kim, G.H. et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010, 121(24): 2661-71.
15. Petkov, V., Mosgoeller, W., Ziesche, R. et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003, 111(9): 1339-46. (Pubitemid 36554704)
16. Jacobs, W., Boonstra, A., Brand, M., Rosenberg, D.M., Schaaf, B., Postmus, P.E., Vonk Noordegraaf, A. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. J Heart Lung Transplant 2010, 29(10): 1150-8.
17. Benza, R.L., Rayburn, B.K., Tallaj, J.A., Pamboukian, S.V., Bourge, R.C. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: longterm efficacy and combination with bosentan. Chest 2008, 134(1): 139-45. (Pubitemid 352008775)
18. Voswinckel, R., Reichenberger, F., Gall, H. et al. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther 2009, 22(1): 50-6.
19. McLaughlin, V.V., Benza, R.L., Rubin, L.J. et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010, 55(18): 1915-22.
20. Voswinckel, R., Reichenberger, F., Enke, B. et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008, 21(5): 824-32.
21. Olschewski, H., Hoeper, M.M., Behr, J. et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010, 104(5): 731-40.
22. Reichenberger, F., Mainwood, A., Morrell, N.W., Parameshwar, J., Zaba, J.P. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Pulm Pharmacol Ther 2011, 24(1): 169-73.
23. Rubin, L.J., Badesch, D.B., Barst, R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346(12): 896-903. (Pubitemid 34984638)
24. Roman, A., Gispert, P., Monforte, V., Bravo, C., Domingo, E., Morell, F. [Long-term outcomes of treatment with bosentan in pulmonary hypertension]. Arch Bronconeumol 2006, 42(12): 616-20.
25. Hoeper, M.M., Faulenbach, C., Golpon, H., Winkler, J., Welte, T., Niedermeyer, J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004, 24(6): 1007-10. (Pubitemid 39642293)
26. Galie, N., Olschewski, H., Oudiz, R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117(23): 3010-9.
27. Oudiz, R.J., Galie, N., Olschewski, H. et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54(21): 1971-81.
28. Blalock, S.E., Matulevicius, S., Mitchell, L.C. et al. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail 2010, 16(2): 121-7.
29. Langleben, D., Brock, T., Dixon, R., Barst, R. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previ- ous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol 2004, 44 Suppl 1: S80-4. (Pubitemid 40039649)
30. Franchi, S.M., Barreto, A.C., Cicero, C., Castro, C.R., Ribeiro, Z.V., Lopes, A.A. [Two-year follow-up of pulmonary arterial hypertension patients treated with sildenafil]. Arq Bras Cardiol 2010, 94(5): 671-7.
31. Simonneau, G., Rubin, L.J., Galie, N. et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149(8): 521-30.
32. Gruenig, E., Michelakis, E., Vachiery, J.L. et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 2009, 49(11): 1343-52.
33. Galie, N., Brundage, B.H., Ghofrani, H.A. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119(22): 2894-903.
34. Wrishko, R.E., Dingemanse, J., Yu, A., Darstein, C., Phillips, D.L., Mitchell, M.I. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008, 48(5): 610-8. (Pubitemid 351503516)
35. Schermuly, R.T., Stasch, J.P., Pullamsetti, S.S. et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008, 32(4): 881-91.
36. Ghofrani, H.A., Hoeper, M.M., Halank, M. et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010, 36(4): 792-9.
37. Grimminger, F., Weimann, G., Frey, R. et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009, 33(4): 785-92.
38. Jing, Z.C., Jiang, X., Wu, B.X. et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart 2009, 95(18): 1531-6.
39. Ikeda, D., Tsujino, I., Sakaue, S. et al. Pilot study of shortterm effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 2007, 71(11): 1829-31. (Pubitemid 350240113)
40. Kunieda, T., Nakanishi, N., Matsubara, H. et al. Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Int Heart J 2009, 50(4): 513-29.
41. Kuwano, K., Hashino, A., Noda, K., Kosugi, K., Kuwabara, K. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)- amino]butoxy}-N-(methylsulfonyl) acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2- yl)(isopropyl)amino] butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008, 326(3): 691-9.
42. Iglarz, M., Binkert, C., Morrison, K. et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008, 327(3): 736-45.
43. Waxman, A.B., Lawler, L., Cornett, G. Cicletanine for the treatment of pulmonary arterial hypertension. Arch Intern Med 2008, 168(19): 2164-6.
44. Ananthakrishnan, M., Barr, F.E., Summar, M.L. et al. L-Citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol 2009, 297(3): L506-11.
45. Perez-Penate, G.M., Julia-Serda, G., Ojeda-Betancort, N. et al. Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension. J Heart Lung Transplant 2008, 27(12): 1326-32.
46. Kureishi, Y., Luo, Z., Shiojima, I. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000, 6(9): 1004-10.
47. Satoh, M., Satoh, A. 3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension. J Pharm Pharm Sci 2008, 11(2): 118s-30s.
48. Zhao, L., Sebkhi, A., Ali, O. et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009, 34(4): 948-57.
49. Wilkins, M.R., Ali, O., Bradlow, W. et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 2010, 181(10): 1106-13.
50. Klein, M., Schermuly, R.T., Ellinghaus, P. et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008, 118(20): 2081-90.
51. Mouchaers, K.T., Schalij, I., de Boer, M.A. et al. Effective reduction of MCT-PAH by fasudil. Comparison with bosentan and sildenafil. Eur Respir J 2010, 36(4): 800-7.
52. Zhang, F., Wu, S., Lu, X., Wang, M., Liu, M. Gene transfer of endothelial nitric oxide synthase attenuates flow-induced pulmonary hypertension in rabbits. Ann Thorac Surg 2008, 85(2): 581-5.
53. Porvasnik, S.L., Germain, S., Embury, J. et al. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther 2010, 334(2): 364-72.
54. Morecroft, I., Pang, L., Baranowska, M. et al. In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res 2010, 85(3): 593-603.
55. Guignabert, C., Raffestin, B., Benferhat, R. et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005, 111(21): 2812-9. (Pubitemid 40791554)
56. Dickstein, K., De Voogd, H.J., Miric, M.P., Willenbrock, R., Mitrovic, V., Pacher, R., Koopman, P.A. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 2004, 94(2): 237-9. (Pubitemid 38902881)
57. Umar, S., de Visser, Y.P., Steendijk, P. et al. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009, 297(5): H1606-16.
58. Takemiya, K., Kai, H., Yasukawa, H., Tahara, N., Kato, S., Imaizumi, T. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol 2010, 105(3): 409-17.
59. Garin, M.C., Clark, L., Chumney, E.C., Simpson, K.N., Highland, K.B. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig 2009, 29(10): 635-46.
60. Adcirca. Destination Rx, May 13, 2010. http://www.destinationrx. com/druginfo.aspx?drugName=Adcirca&drugID=40 941. Accessed July 28, 2010.